Search results for "Chronic kidney disease"
Racial, economic disparities found in use of SGLT-2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
https://immattersacp.org/weekly/archives/2021/04/20/2.htm
20 Apr 2021
Correcting medicine's use of race in clinical algorithms
Recent efforts have pushed institutions to reconsider the use of race not just in estimating kidney function, but in a variety of algorithms and scores.
https://immattersacp.org/archives/2021/05/correcting-medicines-use-of-race-in-clinical-algorithms.htm
1 May 2021
New recommendations advise on adding SGLT-2 inhibitors and GLP-1 receptor agonists
A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, among other advice.
https://immattersacp.org/weekly/archives/2021/05/18/4.htm
18 May 2021
Guideline issued on blood pressure management in CKD
The Kidney Disease: Improving Global Outcomes Work Group recommends targeting a standardized systolic blood pressure less than 120 mm Hg in patients with chronic kidney disease (CKD) who are not receiving dialysis, among other guidance.
https://immattersacp.org/weekly/archives/2021/06/22/4.htm
22 Jun 2021
Residents reimagine antiracism curriculum
Residents interested in diversity, equity, and inclusion are taking matters into their own hands, creating new training initiatives about the subject as a formal part of their medical school curriculum.
https://immattersacp.org/archives/2021/07/residents-reimagine-antiracism-curriculum.htm
1 Jul 2021
Pacemakers, stents recalled; warnings on liver disease drug
This column reviews details on recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2021/07/pacemakers-stents-recalled-warnings-on-liver-disease-drug.htm
1 Jul 2021
MKSAP Quiz: Difficult-to-control hypertension
A 62-year-old man is evaluated during a follow-up visit for difficult-to-control hypertension. He also has chronic kidney disease and hyperlipidemia. Following a physical exam and lab studies, what is the most appropriate additional treatment?
https://immattersacp.org/weekly/archives/2021/08/24/3.htm
24 Aug 2021
NKF-ASN task force issues final report on use of race in diagnosing kidney disease
Effective immediately in the U.S., estimated glomerular filtration rate should be calculated with an updated equation that does not include a race modifier for Black patients, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) said.
https://immattersacp.org/weekly/archives/2021/09/28/2.htm
28 Sep 2021
MKSAP Quiz: Follow-up for stable chronic kidney disease
A 57-year-old man is evaluated during follow-up for stable chronic kidney disease diagnosed 1 year ago. He also has type 2 diabetes mellitus, hyperlipidemia, and peripheral artery disease. On physical examination, blood pressure is 128/74 mm Hg, pulse rate is 65/min, and respiration rate is 18/min. Bilateral carotid and lower abdominal quadrant bruits are heard. Peripheral extremity pulses are diminished. The remainder of the examination is normal. After laboratory studies, what is the appropriate management?
https://immattersacp.org/weekly/archives/2021/11/09/3.htm
9 Nov 2021
Meta-analysis compares mortality benefits of heart failure treatment combinations
Patients taking an angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter-2 inhibitor showed the greatest reduction in risk of death, the analysis of heart failure with reduced ejection fraction found.
https://immattersacp.org/weekly/archives/2021/12/14/4.htm
14 Dec 2021